Preprints vs Peer-Reviewed Studies in Longevity

Preprints are manuscripts shared publicly before formal journal peer review, while peer-reviewed studies have undergone editorial and reviewer evaluation prior to publication. Both can contribute to scientific understanding, but they should be interpreted with different levels of confidence. [1] [2] [3]

In longevity research, where mechanistic findings and biomarker changes are often discussed before clinical outcomes are established, this distinction is especially important. [4] [5]

1. Why Preprints Are Useful

Preprints allow rapid sharing of methods, analyses, and early findings. They can accelerate scientific discussion and make new work visible sooner than traditional journal publication timelines. [1] [2] [6]

This can be helpful for readers tracking emerging geroscience topics, but speed should not be confused with validation. [4] [5]

2. Why Preprints Require Extra Caution

Because preprints have not completed peer review, they may contain unresolved methodological issues, statistical errors, or overconfident conclusions. Some are later revised substantially or not published in the same form. [1] [2] [7]

This does not make preprints unusable; it means readers should treat them as provisional evidence and pay closer attention to methods and limitations. [7] [8]

3. What Peer Review Improves and What It Does Not

Peer review often improves clarity, reporting quality, and error detection, but it does not guarantee that a study is correct or clinically meaningful. Published papers can still be biased, underpowered, or overinterpreted. [8] [9]

Readers should therefore evaluate both preprints and published papers using the same core questions: design, endpoint relevance, effect size, uncertainty, and replication. [9] [10]

4. Practical Checklist for Longevity Preprints

• Is the paper testing a mechanism, biomarker, or clinical outcome?
• Are the methods and statistical analyses described clearly enough to evaluate?
• Are effect sizes and confidence intervals reported?
• Are conclusions limited to what the endpoint can support?
• Has the work been replicated or independently confirmed?
• Has a peer-reviewed version been published, and did the conclusions change?

This matters because early-stage findings in ageing biology do not always translate into human healthspan or lifespan benefits. [4] [5] [10]

5. When to Prefer the Peer-Reviewed Version

If a peer-reviewed version exists, it is usually the better citation for stable summaries because it may include updated analyses, reviewer-requested clarifications, and corrected wording. Comparing the two versions can also show how the evidence changed over time. [3] [7]

Summary

Preprints are useful for discovering emerging longevity research, but they should be read as preliminary. Peer-reviewed studies deserve more weight, but still require critical appraisal. The most reliable approach is to evaluate both by methods, endpoints, and replication rather than publication status alone. [8] [9] [10]

References

1. About bioRxiv.
2. About medRxiv.
3. PubMed Central (PMC): Preprints in PMC.
4. National Institute on Aging (NIA): Geroscience and the intersection of aging biology and chronic disease.
5. Justice JN, et al. Frameworks for proof-of-concept clinical trials of interventions that target fundamental aging processes. Journals of Gerontology A (2018).
6. ASAPbio: Preprint FAQ.
7. Fraser N, et al. Preprinting a pandemic: the role of preprints in the COVID-19 pandemic. bioRxiv/PLoS Biology context paper (2020).
8. Ioannidis JPA. Why Most Published Research Findings Are False. PLoS Medicine (2005).
9. Guyatt GH, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (2008).
10. López-Otín C, et al. The Hallmarks of Aging. Cell (2013).